Biopharma: neuroinflammation, next-gen genetically engineered microbe / cell / gene therapies, gene therapy and cell therapy for neuro and autoimmune disease, s

Biopharma: neuroinflammation, next-gen genetically engineered microbe / cell / gene therapies, gene therapy and cell therapy for neuro and autoimmune disease, small molecules targeting genetically defined neuro, cardiovascular and autoimmune disease, chemogenetics, programming languages for specific parts of the bio stack $17B invested in bio startups in 2018, very little of it by traditional tech VCs One $11B exit < 5 years from series a (Juno), one $9B exit ~4 years from series a (avexis), one $8b mkt cap ipo, one $8b exit from ~5 year old company to start 2019 (loxo), multiple smaller billion+ exits, ~50 vc backed IPOs Several innovative companies launching their first drugs soon, potential to become standalone commercial companies: sage, agios, alnylam, Ionis / akcea, bluebird, ultragenyx, gw pharma